Skip to main content

Table 1 Baseline characteristics of the intent-to-treat (ITT) population (N = 147)

From: Impacts of metabolic disruption, body mass index and inflammation on cognitive function in post-COVID-19 condition: a randomized controlled trial on vortioxetine

Characteristic

Placebo

(n = 74)

Vortioxetine

(n = 73)

p-value*

Age (Years), Mean (SD)

44.89 (12.14)

43.84 (12.35)

0.602a

Sex (Female), n (%)

55 (74.32)

56 (76.71)

0.736b

Education, n (%)

0.390b

< High School

0 (0)

1 (1.37)

 

High School Graduate

4 (5.41)

8 (10.96)

College/University Degree

10 (13.51)

7 (9.59)

Associates Degree

15 (20.27)

13 (17.81)

Bachelor’s Degree

27 (36.49)

34 (46.58)

Graduate Degree

15 (20.27)

9 (12.33)

Professional Degree

3 (4.05)

1 (1.37)

Confirmed COVID Diagnosis, n (%)

59 (79.7)

57 (78.1)

0.807b

QIDS-SR-16 (Total Score), Mean (SD)

10.32 (4.37)

10.03 (4.33)

0.681a

MDD Diagnosis, n (%)

25 (33.78)

22 (30.14)

0.595b

FSS (Total Score), Mean (SD)

51.84 (10.20)

49.78 (10.96)

0.083a

Walking Days per Week, Mean (SD)

4.18 (2.53)

4.62 (2.43)

0.283a

Remote Assessment, n (%)

69 (93.24)

67 (91.78)

0.736b

Combined DSST Z-score, Mean (SD)c

-0.194 (0.99)

0.0531 (1.01)

0.136a

CRP, Mean (SD)

3.07 (3.37)

2.43 (2.96)

0.276a

TRG-HDL, Mean (SD)

3.62 (0.99)

5.81 (17.19)

0.376a

BMI, Mean (SD)

31.25 (7.49)

29.03 (9.05)

0.113b

Normal Weight

21.99 (2.31)

22.57 (1.52)

 

Overweight

27.93 (1.40)

27.69 (1.56)

Obese

37.99 (4.98)

40.51 (8.33)

  1. aT-test
  2. bChi-square test
  3. cCombined DSST z-score defined as the equally weighted sum of the z-scores in the combined DSST (Pen/Paper plus Online CogState Version)
  4. *Two-sided p values;
  5. Abbreviations: BMI = Body Mass Index; CRP = C-Reactive Protein; DSST = Digit Symbol Substitution Test; FSS = Fatigue Severity Scale; MDD = Major Depressive Disorder; QIDS-SR16 = Quick Inventory of Depressive Symptomatology-Self-Report 16; SD = Standard Deviation; TRG-HDL = Triglyceride / HDL-Cholesterol.